|
|
|
26.10.26 - 02:00
|
Results: SINOPHARM 9M Net Profit RMB5.314B (AAStocks)
|
|
|
SINOPHARM (01099.HK) announced its results for the first three quarters ended September 2026. Revenue was RMB427.613 billion, down 0.90% YoY. Net profit was RMB5.314 billion, up 0.13% YoY. EPS was RMB1.70. (su)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version sh......
|
|
|
26.08.26 - 08:45
|
Research: G Sachs: SINOPHARM 2Q Results In Line, Cuts TP to HKD18.46 (AAStocks)
|
|
|
G Sachs issued a report stating that SINOPHARM (01099.HK)'s second-quarter sales fell 1.6% YoY to RMB142.4 billion, broadly in line with expectations. Gross margin came under pressure at 7.05%, below 7.46% in the same period last year, mainly due to the continued rollout of volume-based procurement (VBP) for pharmaceuticals and ......
|
|
|
|
|
25.08.26 - 08:30
|
SINOPHARM Falls 3.6% as Citi Cuts TP to HKD20.4 (AAStocks)
|
|
|
SINOPHARM (01099.HK) opened 2.02% lower today and hit a trough of HKD15.67. It is now trading at HKD15.75, down 3.55%, with turnover of 6.3919 million shares involving HKD101 million.Citi said in a report that SINOPHARM's first-half results missed expectations. Revenue was RMB282.8 billion, down 1.1% YoY, 2.3% below the broker's......
|
|
|
|
|
17.08.26 - 17:00
|
SINOPHARM Subsidiary SINOPHARM ACCORD 1H26 Net Profit RMB606 million, Down 9% (AAStocks)
|
|
|
SINOPHARM (01099.HK) announced that its subsidiary SINOPHARM ACCORD (000028.SZ) reported results for the first half of the year. Total operating revenue was RMB36.266 billion, down 1.4% YoY. Net profit attributable to shareholders was RMB606 million, down 9%. EPS was RMB0.99. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.c......
|
|
|
|
|
|
|
09.07.26 - 10:00
|
Research: Daiwa Downgrades SINOPHARM to Hold, Cuts TP to HKD18 (AAStocks)
|
|
|
Daiwa said in a report that SINOPHARM (01099.HK)'s revenue has started to stabilize, but there is not yet a clear timetable for a rebound. Guidance for retail pharmacy revenue in 2026 indicates double-digit YoY growth. The rating was downgraded from "Outperform" to "Hold", while the target price was lowered from HKD21 to HKD18. ......
|
|
|
15.06.26 - 07:15
|
SINOPHARM Establishes Strategic Partnership with Pfizer, Inc. (AAStocks)
|
|
|
SINOPHARM (01099.HK) has recently formally established a strategic partnership with Pfizer, Inc. (PFE.US). The two parties will focus on the upgraded market promotion of Diflucan (fluconazole sodium chloride injection/fluconazole capsules), as well as in-depth cooperation on service enhancements for Pfizer's future new products.......
|
|
|
|
|
|
|
28.04.26 - 06:00
|
Research: CLSA Raises Sinopharm TP to HKD25, Maintains Outperform (AAStocks)
|
|
|
CLSA published a research report stating that Sinopharm (01099.HK)'s results last year were in line with expectations. Revenue in 4Q rose 1.1% YoY, while gross margin and operating profit margin narrowed by 0.62 ppts and 0.71 ppts, respectively. Benefiting from improved financial leverage and reduced finance costs, net profit st......
|
|
|
27.04.26 - 02:30
|
Sinopharm 1Q26 Net Profit RMB1.41 Billion, Down 3% YoY (AAStocks)
|
|
|
Sinopharm (01099.HK) announced its results for 1Q26 ended March, prepared in accordance with China Accounting Standards for Business Enterprises. Revenue amounted to RMB140.77 billion, down 0.6% YoY. Net profit was RMB1.41 billion, down 3% YoY. EPS was RMB0.45. (jl/w)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article ......
|
|
|
22.04.26 - 16:00
|
Sinopharm Subsidiary Sinopharm Co 1Q Net Profit RMB474M, Up 3.3% (AAStocks)
|
|
|
Sinopharm (01099.HK) announced that its subsidiary Sinopharm Co (600511.SH) released its first-quarter report. Revenue amounted to RMB13.555 billion, representing a YoY increase of 6.6%. Net profit attributable to shareholders reached RMB474 million, up 3.3%, with EPS at RMB0.6286. (de/d)~AASTOCKS Financial NewsWebsite: www.aast......
|
|
|
|
|
|
|
23.03.26 - 02:15
|
Results: SINOPHARM Annual NP Grows 1.5% to RMB7.155B; Final Div. RMB0.69 (AAStocks)
|
|
|
SINOPHARM (01099.HK) has announced its annual results for the period ended December 2025.The company's turnover declined by 1.6% YoY to RMB575.168 billion, while net profit amounted to RMB7.155 billion, up 1.5% YoY, with EPS at RMB2.29.A final dividend of RMB0.69 was declared, compared to the dividend of RMB0.68 in the same ......
|
|
|
19.03.26 - 14:48
|
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials (PR Newswire)
|
|
|
BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
